Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Large Decrease in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 83,700 shares, a drop of 63.1% from the November 30th total of 226,700 shares. Approximately 0.5% of the shares of the company are short sold. Based on an average trading volume of 449,700 shares, the days-to-cover ratio is currently 0.2 days.

Sensei Biotherapeutics Stock Up 3.9 %

Sensei Biotherapeutics stock traded up $0.02 during midday trading on Friday, reaching $0.50. The stock had a trading volume of 240,551 shares, compared to its average volume of 207,308. The firm has a market capitalization of $12.53 million, a PE ratio of -0.42 and a beta of 0.16. Sensei Biotherapeutics has a 12 month low of $0.38 and a 12 month high of $1.94. The firm’s 50-day moving average price is $0.51 and its 200 day moving average price is $0.56.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI boosted its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,575 shares of the company’s stock after buying an additional 35,575 shares during the period. National Bank of Canada FI owned approximately 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.